Related Experiment Video
Updated: Mar 12, 2026
09:34
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
2.3K
Granulomas and Inflammation: Host-Directed Therapies for Tuberculosis
Hlumani Ndlovu1, Mohlopheni J Marakalala2
1Division of Immunology, Department of Pathology, University of Cape Town , Cape Town , South Africa.
Frontiers in Immunology
|November 9, 2016
Summary
Tuberculosis (TB) treatment requires new strategies due to drug resistance. Understanding host factors and granuloma roles can lead to host-directed therapies (HDTs) to improve outcomes.
Area of Science:
- Immunology
- Pathogenesis
- Microbiology
Background:
- Tuberculosis (TB) is a major global health issue exacerbated by drug-resistant strains, leading to treatment failures.
- Effective eradication of TB necessitates novel therapeutic strategies beyond conventional antibiotics.
- Host-directed therapies (HDTs) offer a promising avenue by targeting host responses to potentiate anti-mycobacterial immunity.
Approach:
- This review synthesizes current knowledge on the role of granulomas in TB pathogenesis and immunity.
- It examines clinical and animal model studies to understand granuloma dynamics.
- The review explores therapeutic targets within inflammatory pathways driving granuloma progression.
Key Points:
- Granulomas are crucial immune structures in TB, but their progression can lead to cavities and facilitate bacterial spread.
- Host factors influencing granuloma formation and evolution are key targets for adjunct therapies.
- Modulating inflammatory pathways within granulomas holds potential for improving TB treatment outcomes.
Conclusions:
- Identifying host factors is critical for developing effective HDTs against TB.
- Targeting granuloma progression and associated inflammation may overcome drug resistance.
- Integrated therapeutic strategies combining anti-mycobacterials with HDTs are essential for TB eradication.
Related Concept Videos
01:28Pulmonary Tuberculosis II
1.8K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.8K
01:28Pulmonary Tuberculosis V
726
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
726
01:26Pulmonary Tuberculosis IV
600
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
600
01:29Pulmonary Tuberculosis I
1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
01:31Pulmonary Tuberculosis III
1.3K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
1.3K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
692
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
692